EntryPoint Capital’s Procept Biorobotics PRCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$324K Buy
+14,359
New +$360K 0.08% 514
2025
Q3
Sell
-3,780
Closed -$218K 836
2025
Q2
$218K Sell
3,780
-145
-4% -$8.2K 0.11% 445
2025
Q1
$229K Sell
3,925
-1,348
-26% -$92K 0.1% 473
2024
Q4
$425K Sell
5,273
-577
-10% -$49.3K 0.18% 177
2024
Q3
$469K Buy
5,850
+2,337
+67% +$166K 0.27% 70
2024
Q2
$215K Buy
3,513
+2,669
+316% +$159K 0.1% 372
2024
Q1
$41.7K Buy
844
+38
+5% +$1.81K 0.04% 848
2023
Q4
$33.8K Buy
+806
New +$27.4K 0.03% 884

Other funds holding PRCT

EntryPoint Capital's PRCT Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Procept Biorobotics (PRCT) in Q2 2026: 14,359 shares worth $324K. The stake represents 0.08% of the portfolio and ranks #514 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in PRCT as recently as Q2 2025.

EntryPoint Capital first reported a position in PRCT in Q4 2023 and has held it in 8 quarters since. The position peaked at $469K in Q3 2024. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • EntryPoint Capital held 14,359 shares of Procept Biorobotics worth $324K as of Q2 2026.
  • Procept Biorobotics was a new EntryPoint Capital position in Q2 2026.
  • Procept Biorobotics made up 0.08% of EntryPoint Capital's portfolio in Q2 2026, its #514 holding.
  • EntryPoint Capital first reported a position in Procept Biorobotics in Q4 2023 and has held it in 8 quarters since.
  • EntryPoint Capital's Procept Biorobotics position peaked at $469K in Q3 2024.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.